Amir Weiss - 28 Feb 2022 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role
Chief Accounting Officer
Signature
/s/ Dov Bergwerk as attorney-in-fact for Amir Weiss
Issuer symbol
TEVA
Transactions as of
28 Feb 2022
Net transactions value
$0
Form type
4
Filing time
02 Mar 2022, 06:55:36 UTC
Previous filing
06 Dec 2021
Next filing
08 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TEVA Ordinary Shares Options Exercise +3,219 +22% 17,610 28 Feb 2022 Direct F1, F2
transaction TEVA Ordinary Shares Options Exercise +981 +5.6% 18,591 02 Mar 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TEVA Restricted Share Units Options Exercise $0 -3,219 -33% $0.000000 6,438 28 Feb 2022 Ordinary Shares 3,219 Direct F1, F2, F3
transaction TEVA Restricted Share Units Options Exercise $0 -981 -100% $0.000000* 0 02 Mar 2022 Ordinary Shares 981 Direct F1, F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2 Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3 Restricted share units were granted on February 28, 2020, with 3,219 having vested on each of February 28, 2021 and February 28, 2022, and 3,219 vesting on each of February 28, 2023 and February 28, 2024.
F4 Restricted share units were granted on March 3, 2018 and vested on March 2, 2022.